Trial · NCT00047879
Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
NCT00047879, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2011-10-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas. Trials, record NCT00047879. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00047879
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas
- NCT number
- NCT00047879
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Glioma
- Interventions
- PEG-interferon alfa-2b, Thalidomide
- First posted
- 2002-10-23
- Last updated
- 2011-10-26
- Results first posted
- 2011-10-26
- Limitations and caveats
- Registered 7 out of 64 participants and they came off study for progressive disease around 3-4 months after starting the study.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival | 6 months | Progression free survival is defined as the percent of patients that are progression free and alive 6 months after initiating therapy. Progression of disease by \> 50% increase in the size of the tumor compared to baseline after the first cycle only, and then \>25% increase in the size of the tumor for all subsequent cycles. |
| Secondary | Number of Participants With Complete or Partial Response | 6 months | Response is defined per RECIST criteria. Measurable disease is defined as bidimensionally measurable lesions with clearly defined margins by CT or MRI scan. Evaluable disease is defined as unidimensionally measurable lesions, masses with margins not clearly defined, or lesions with a multiple cystic component. Complete response (CR) is complete disappearance of all measurable and evaluable disease. Partial response (PR) is greater than or equal to 50% decrease under baseline in the sum of products or perpendicular diameters of all measurable lesions. |
| Secondary | The Number of Participants With Adverse Events | 4 months | Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival | 6 months | The primary objective was not met. Only registered 7 out of 64 participants and they all came off the study for progressive disease around 3-4 months after starting the study. None of the participants were evaluated for progression-free survival at 6 months because the study was stopped at 4 months due to progressive disease. | Percent of participants | NUMBER |
| SECONDARY | Number of Participants With Complete or Partial Response | 6 months | Registered 7 out of 64 participants and they came off study for progressive disease around 3-4 months after starting the study. | Participants | NUMBER |
| SECONDARY | The Number of Participants With Adverse Events | 4 months | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Number of Participants With Adverse Events | Glioblastoma Multiforme Stratum | 4 | Participants | ||
| The Number of Participants With Adverse Events | Anaplastic Glioma Stratum | 2 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Glioblastoma Multiforme Stratum | 4 | |
| Overall Study | STARTED | Anaplastic Glioma Stratum | 3 | |
| Overall Study | COMPLETED | Glioblastoma Multiforme Stratum | 0 | |
| Overall Study | COMPLETED | Anaplastic Glioma Stratum | 0 | |
| Overall Study | NOT COMPLETED | Glioblastoma Multiforme Stratum | 4 | |
| Overall Study | NOT COMPLETED | Anaplastic Glioma Stratum | 3 |
Source ClinicalTrials.gov
Adverse events54
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | edema: limb right upper extremity | General disorders | Glioblastoma Multiforme Stratum | 0 | 4 | 0 |
| other | edema: limb right upper extremity | General disorders | Anaplastic Glioma Stratum | 1 | 3 | 1 |
| other | Thrombocytopenia | Investigations | Glioblastoma Multiforme Stratum | 0 | 4 | 0 |
| other | Thrombocytopenia | Investigations | Anaplastic Glioma Stratum | 1 | 3 | 1 |
| other | Fatigue | General disorders | Glioblastoma Multiforme Stratum | 2 | 4 | 3 |
| other | Fatigue | General disorders | Anaplastic Glioma Stratum | 0 | 3 | 0 |
| other | Dizziness | Nervous system disorders | Glioblastoma Multiforme Stratum | 1 | 4 | 1 |
| other | Dizziness | Nervous system disorders | Anaplastic Glioma Stratum | 0 | 3 | 0 |
| other | Infection | Infections and infestations | Glioblastoma Multiforme Stratum | 1 | 4 | 1 |
| other | Infection | Infections and infestations | Anaplastic Glioma Stratum | 0 | 3 | 0 |
1 to 10 of 54Source ClinicalTrials.gov
See all 54 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Glioblastoma Multiforme Stratum | ||
| Total, all-cause mortality | Anaplastic Glioma Stratum | ||
| Total, other adverse events | Glioblastoma Multiforme Stratum | 4 | 4 |
| Total, other adverse events | Anaplastic Glioma Stratum | 2 | 3 |
| Total, serious adverse events | Glioblastoma Multiforme Stratum | 3 | 4 |
| Total, serious adverse events | Anaplastic Glioma Stratum | 2 | 3 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Glioblastoma Multiforme Stratum vs Anaplastic Glioma Stratum: The Number of Participants With Adverse Events | Trial comparisons |
| Glioblastoma Multiforme Stratum vs Anaplastic Glioma Stratum: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00047879
GET https://conductscience.org/api/trials/v1/NCT00047879/events?page=2